discuss open call transition quarter quarter then by in the questions. begin future Sullivan, you, Chief for Officer, of update first the Trip, and Thank achieved that Senseonics. financials growth will and our the on the critical we'll Financial for up thank joining milestones catalysts us and providing by recently an Then Rick detail, the company today represent first performance the you afternoon. We'll several for this all our important during to
to advanced initiatives key We've had long-term CGM We've implantable to to the benefits at a year intended of to strategic appeal more amplify successful start Senseonics. the patients. our very
advancing by in systems quarter-over-quarter making largest and patient one of the with both XX new with additions a commercial progress the transformational our are health country. growth collaboration We in
Eversense facilitate to to foundational care targeted diabetes population. has to the program intended large in population patient a as Mercy technology optimize chosen broad-based use a management
new Importantly, product monitoring for from we as approval, submission achieving as patient establishing product. and solution the the have progressed filing designation remote the iCGM recent pipeline XXX-day Eversense by our our FDA significantly well next-generation XXX(k)
advancement and the build product development new the With strongest in Eversense the fits remainder the these ever. to XXXX. throughout anticipate position of pipeline we initiatives, accomplishments commercial platform of continuing of We the believe its on
generated In On the front, $X.X U.S., quarter, the representing prior totaled sales sales U.S. in first $X.X $X.X the outside growth million million. and Senseonics the quarter totaled financial year the to period. million, total XX% first revenue compared of
their driving Diabetes population. both to They front, growth with professional On remain awareness efforts. a within DTC access to Eversense rooted expanded Care, continue by Ascensia and drive patient sales in the commercial and objectives main the diabetes quarter-over-quarter
appointed to President business the recently Senseonics' has we Brian the previously as announced, was veteran, Additionally, of also industry ADC Hansen Board. CGM and appointed been have
role ramps We closely and execution. this he are together and strategy to as working commercial Eversense plans improve into formalizes
patient for that eligible similar both helping cost Eversense health patients patients the improve reduce organizations care large pressures X/X managed not with while to across adoption quality we on notably, less many lives.
To care driving systems down to we of and suited for is of one, of additional continue a accountable patients expansion with while for sub-optimally resulting by their history of remains diabetes estimate integration diabetes. on Eversense, economic Medicare there clinical care than CGM explore Importantly, the believe are as costs health giving are avenues for all using diabetes, well ideally with that CGM cover to from commercial for as the payers, using benefits to by we insulin, care outcomes people CGM who healthier opportunity insulin and growth and live hypoglycemia.
And now substantial increased health patients end, all facing
benefit primary from the broad efficient specifically workflows care these manage our in With to cardiologists, CGM. professionals people as the ability the could systems office-based of diabetes, breadth physicians, endocrinologists of influence pathways and who their we care with who conduct procedures adoption patient and system, such to Eversense the with for would believe including those care providers interventional enable their regularly health together and certainly implantable
advanced better to patients avoid We to risk. coming these estimated quarters their the patients in substantial who innovative look For this announced their in Missouri, consistently spans is to expenditures. Eversense this accountable diabetes this across leading clearly represents bring and data their years identified capabilities benefit and in innovative states systemically across intelligence program.
Together, breakthroughs Mercy we system, long-term care we for an this working management Eversense with analytics forward care we are system, health recognized manage RPM costly artificial monitor front, an based health has recognizes care. Mercy's Ascensia patients Eversense a to bring collaboration can its could to opportunity can as multistate CGM, we Louis, health X Mercy Eversense with out St. roll at with our potential our innovative today, combines CGM.
We collaboration a Mercy. from many Mercy, to the to with population diabetes XX,XXX program an and organization approach help that as and of these up and believe value new short- working build to patients as
emphasis to and Eversense XXX-day patients in cohort controlled We Louis X the insulin on Mercy's executives of to adoption with patients product conjunction the launch to the targeted initially we'll QX.
Together, then with place ramp Type planned the plans operations basal program. to making to trailed and in for see in who we teams further St. July, a operational technologies. Mercy look of design on working available launch an historically advanced are in opportunity implement metro a the focused on begin and area
Our perspective advanced both patient that personalized patient the to the care can remote is and and to system. technologies risk reduce health access monitoring
use innovation be goal is with comprehensive develop other so leadership to can health shared diabetes Mercy for their to replicated it this Our management care approach organizations. that
by could RPM which health approach we An the providers health X,XXX estimated strategic the collaboration excited patients an important to believe value are for Eversense newly systems. Eversense a component will solution comprehensive further bring to includes and systems. this of With program, systems enhance U.S., we in care to Eversense announced the this develop providing health our differentiate
there an between While often established with visits. even ongoing opportunity that CGM support deliver it alone there patients utilizing better particularly we for to office for limited is personal has Today, the more. feel been are produces people but provided understanding data is we're well and confident a simply device, diabetes, for in CGM outcomes optimization
program in these RPM to key fill gaps. Our aims
glucose it and by counselors designed use through better their intent optimal to provide for patients participants designed a are to and as supported counselors. the insight to remedy data exercise things First, diabetes.
The for it the RPM their provide intended with better to device, These food the and requirements understanding CGM with coaching is how program of commercial to control, Medicare and impacting diabetes into strong in is glucose reimbursement. and their medications, program, enable meet levels about make informed to and such Mercy managing choices foundation
a the communication and between patient's health optimization we an enabling providing our basis, RPM monthly provider to also see loop. counselors patients By aim invaluable addition, on In improve loop the key we interventions. program with as care this engaging
corrective occurred to office development and reasons this the their We business, the build will for combination be and more and we RPM appropriate choice. finalized an we accelerating solution done make in CGM Eversense see program be and our Eversense the We intend to visits.
After and clinicians able providing rolled Eversense between making important out now The changes, traditional goal is which program that to make Eversense and and have the with to use are of comprehensive implementation clinicians identifying generally. further. care Mercy previously to patients believe is the with of need it system progress bridging for of visits, more Mercy, actions in-person gap testament during CGM improvement excited who partnership RPM as this between available
plan we ADA conference. these developing to second year As we We for the our provide opportunities, year the June occur the finalize plans which expected at in full year, in are upcoming guidance half outlook. our financial full the to are of
Senseonics half over growth half for continue As net of of be expect revenue to we XX% to XXXX, for global first the the $XX million, XXXX. representing first approximately of
manages as with revenue consistent new is Second levels. quarter towards inventory to assumes normalizing growth, the quarter be Ascensia continued patient and revenue expected in first the
I'll our in in pipeline. pipeline for Senseonics. our key product technology progress X today remains milestones development Now of And highlight teams. with to our focus turn key CGM broader innovation continuing pleased advance I'm We're a to strategic to important plan. the imperative
including CGM recently the can automated medical designation the delivery iCGM integrate insulin product Eversense iCGM FDA. of received we with iCGM First, devices, Eversense announced an as insulin system the The compatible designation system. the that from pumps part indicates
with to is are offer leading a with to new with aim core that insulin we to Class devices for excited suited FDA's discussion well this systems. by step automated fully we stages category, delivery integrated iCGM updates and accuracy been Eversense is an be a in delivery our system, authorized type We and option through as plan and initiatives we that partnership marketed to authorization the next of as the FDA the device for submissions. performance further in to exceptionally advance component pathway.
This and opportunity forward for discussions. more as Senseonics as potential they companies.
At pipeline, X been bar first develop. various with point, substantially interoperable diabetes manufacturers all excited advance impact submitted insulin Eversense future people an our set Both believe recognize pump de and CGM move of the and lives integration the to of discussions strategic designation we're provide similar The positively to be the with the As Eversense has these implanted to people demonstrates the intent by high iCGM has XXX(k) meets more device to are equivalent manufacturers devices novo the our analytical
second development. for key Now our pipeline exciting
our to this our last the our for novo type. are same for iCGM approval, facilitated down-regulation notification. as FDA submission filed de designation week, a this iCGM of we we Following devices report, This today, next-generation premarket XXX-day system, pleased of submission XXX(k)
confidence PMA despite work submission submission. high-quality clinical together the generated several our on submission, note this work of have pathway, a system our unique that is towards continue I differentiators. and with and high-quality being would a like a quarter Relying to rigor it goal now XXX-day the in fourth data in same we technology launch put a we offers XXX(k) to as on year.
The to that
anticipated single a in an sensor frequency. protection planned significant calibration full First, reduction year and from a
are calibration reduced a excited confident with will that submission and a goal. moves X-year combination us closer are important that sensor be to this We step that compelling one
transmitter. Importantly, the subsequent are XXX-day for approval and the and for self-powered work Both removing is technology this we as life also leverage our on-body designed development FDA pipeline. and need approaching generation longer platform now goal of the system retained for further products any of with the towards basis capability within to our redundant accuracy Gemini Freedom sensing
We're the excited second Gemini plan testing half be the of to for this in-human in year. of to first continue on
continue technology move pipeline CGM our progression continue our to to prioritize innovate, forward. We to
review I'll of call turn news, the exciting for our now a over to this With financials. Rick
